A catalytic redox-cycling nanoreactor enables robust oxidative stress amplification for synergistic tumor apoptosis and ferroptosis
Source abstract
Abstract
Intervening in the aberrant redox homeostasis of tumors, particularly toward reactive oxygen species (ROS) overload, holds considerable promise for cancer therapy, yet, is severely constrained by the robust compensatory antioxidant defense system (ADS) and the unavoidable disruption of redox homeostasis in normal tissues. Here, we present a catalytic redox-cycling nanoreactor, TEMPO radical-modified cross-linked lipoic acid nanoparticles (T@cLAN), designed to achieve robust oxidative stress amplification for cancer therapy. Lipoic acid (LA) characterized by a cyclic disulfide backbone enables intermolecular thiol-disulfide exchange to from GSH-responsive crosslinked networks, while enabling reversible interconversion with dihydrolipoic acid (DHLA), which can further participate in redox modulation. Mechanistically, T@cLAN depletes intracellular glutathione (GSH) and undergoes depolymerization to generate dihydrolipoic acid (DHLA), which actively participates in redox processes to enhance ROS production. TEMPO, functions as a catalyst rather than a stoichiometric scavenger, directly accelerating the endogenous LA/DHLA redox cycle, thereby further amplifying DHLA generation and sustaining both GSH depletion and ROS amplification. As validated by both in vitro and in vivo results, T@cLAN dismantles the major ADS barrier limiting tumor oxidative stress, achieving an overall 85% GSH depletion and elevating ROS levels by 37-fold compared to untreated tumor cells. Concurrently, it induces both apoptosis and ferroptosis, attaining a tumor inhibition rate of 80% while causing minimal impact on normal cells and tissues, underscoring its substantial potential for cancer therapy. STATEMENT OF SIGNIFICANCE: We engineer a nanoreactor (T@cLAN) as an innovative modality to address a central limitation of oxidative stress-mediated anticancer therapy, that is, the therapeutic attenuation imposed by the highly developed antioxidant defense machinery of tumor cells. T@cLAN is activated by intracellular glutathione, a key redox buffer, to engage two interlinked redox catalytic cycles, enabling sustained glutathione depletion and the amplified accumulation of cytotoxic reactive oxygen species. Through this cooperative redox reprogramming, T@cLAN promotes tumor cell apoptosis and ferroptosis, leading to pronounced anticancer activity. Notably, T@cLAN is activated within the tumor microenvironment while remaining largely quiescent in normal cells, reflecting an active and highly selective intervention mechanism that offers new directions for oxidative stress driven therapeutic innovation.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Biochemical Acid Research Studies · Sulfur Compounds in Biology · Cancer, Hypoxia, and Metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Role of the sulfur-containing amino acid-ROS axis in cancer chemotherapeutic drug resistance10.1016/j.drup.2025.101238 ↗
2. The role of ROS in tumor development and progression10.1038/s41568-021-00435-0 ↗
3. Reactive oxygen species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
4. Nanoplatform-based cellular reactive oxygen species regulation for enhanced oncotherapy and tumor resistance alleviation10.1016/j.cclet.2023.108300 ↗
5. Peroxidase-like active nanomedicine with dual glutathione depletion property to restore oxaliplatin chemosensitivity and promote programmed cell death10.1021/acsnano.1c06777 ↗
6. Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review10.1186/s12951-024-02859-w ↗
7. The pleiotropic functions of reactive oxygen species in cancer10.1038/s43018-024-00738-9 ↗
8. Engineering nanomedicine for glutathione depletion-augmented cancer therapy10.1039/D0CS00718H ↗
9. Carrier-free nanodrugs with efficient drug delivery and release for cancer therapy: from intrinsic physicochemical properties to external modification
10. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment10.1016/j.cclet.2022.05.032 ↗
11. The catalytic reaction of nitroxides with peroxyl radicals and its relevance to their cytoprotective properties10.1021/jacs.8b00998 ↗
12. Extremely fast hydrogen atom transfer between nitroxides and HOO· radicals and implication for catalytic coantioxidant systems10.1021/jacs.8b06336 ↗
13. Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles10.1016/j.biomaterials.2020.120645 ↗
14. Targeting apoptosis in cancer therapy10.1038/s41571-020-0341-y ↗
15. Newton · Cell Death Cell · 2024 · 187 · 235
16. Emergence of large-scale cell death through ferroptotic trigger waves10.1038/s41586-024-07623-6 ↗
17. Cross-linked selenolipoic acid nanoplatform modulates intracellular and extracellular reactive oxygen species for cancer immunotherapy10.1016/j.jconrel.2025.114130 ↗
18. Nanodrug hijacking blood transferrin for ferroptosis-mediated cancer treatment10.1021/jacs.4c00395 ↗
19. Dual-responsive nanogels with high drug loading for enhanced tumor targeting and treatment10.1016/j.cclet.2024.110775 ↗
20. α-lipoic acid induces apoptosis in human colon cancer cells by increasing mitochondrial respiration with a concomitant O2−·-generation10.1007/s10495-005-0810-x ↗
21. Copper induces cell death by targeting lipoylated TCA cycle proteins10.1126/science.abf0529 ↗
22. Radical dendrimers: synthesis, anti-tumor activity and enhanced cytoprotective performance of TEMPO free radical functionalized polyurethane dendrimers10.1016/j.eurpolymj.2019.109354 ↗
23. Dietary pro-oxidant therapy by a vitamin K precursor targets PI 3-kinase VPS34 function10.1126/science.adk9167 ↗
24. Nitroxide-functional PEGylated nanostars arrest cellular oxidative stress and exhibit preferential accumulation in co-cultured breast cancer cells10.1039/D1TB00812A ↗
25. 2,2,6,6-tetramethylpiperidin-1-oxyl: a new potential targeted ligand based on lipid peroxidation for targeted drug delivery10.1080/1061186X.2025.2474639 ↗
26. Thiol-mediated uptake10.1021/jacsau.1c00128 ↗
27. Glutathione-depleting nanomedicines for synergistic cancer therapy10.1021/acsnano.1c00498 ↗
28. Reactive oxygen species and c-jun N-terminal kinases contribute to TEMPO-induced apoptosis in L5178Y cells10.1016/j.cbi.2015.04.009 ↗
29. Pro-oxidative activity of nitroxides in their reactions with glutathione10.1016/S0891-5849(03)00306-X ↗
30. A multifunctional anti-inflammatory drug that can specifically target activated macrophages, massively deplete intracellular H2O2, and produce large amounts CO for a highly efficient treatment of osteoarthritis10.1016/j.biomaterials.2020.120155 ↗
31. Coordinated regulation of BACH1 and mitochondrial metabolism through tumor-targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy10.1016/j.apsb.2022.06.009 ↗
32. Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -710.1126/sciadv.aau9433 ↗
33. Capsular polysaccharide from the marine bacterium Cobetia marina induces apoptosis via both caspase-dependent and mitochondria-mediated pathways in HL-60 cells10.1016/j.carbpol.2024.122791 ↗
34. A ferroptosis-reinforced nanocatalyst enhances chemodynamic therapy through dual H2O2 production and oxidative stress amplification10.1016/j.jconrel.2024.01.049 ↗
35. Lipoic acid-locked reduction-responsive core-cross-linked micelles delivering paclitaxel for triple-negative breast cancer treatment10.1016/j.cclet.2024.110570 ↗